Which company produces Mavakatai (Maifantuo) and a detailed introduction to its research and development background?

Mavacamten, trade name Camzyos, is an oral small molecule cardiac myosin inhibitor, mainly used to treat patients with hypertrophic cardiomyopathy (HCM), especially patients with symptomatic obstructive type HCM. The drug was developed by the American biopharmaceutical company MyoKardia, which was acquired by Bristol Myers Squibb in 2020 and became its wholly-owned subsidiary.

MyoKardia was established in2015, focusing on the research and development of innovative drugs in the field of cardiovascular diseases. In its early days, MyoKardia has been committed to developing precision therapeutic drugs for cardiomyopathy. MavacamtenAs the first clinical candidate drug developed by the company, it has been verified through multiple rounds of clinical trials and has shown significant efficacy in improving cardiac function and symptoms in patients with hypertrophic cardiomyopathy.

In 2020, Bristol-Myers Squibb acquired MyoKardia for 13.1 billion, further strengthening its research and development capabilities in the field of cardiovascular diseases. After the acquisition is completed, Mavacamten will become an important part of Bristol-Myers Squibb's cardiovascular product line. In 4 months of 2022, Mavacamten was approved by the US FDA and became the first cardiac myosin inhibitor approved for the treatment of obstructive hypertrophic cardiomyopathy.

Currently, Mavacamten has been launched in the United States, Japan, Australia, Canada, Macau and other countries and regions, and has obtained corresponding regulatory approvals. In China,Mavacamtenobtained marketing approval from the National Medical Products Administration of China (NMPA) in 2023, and United Lab (LianBio) is responsible for commercialization in mainland China. The launch of this drug provides a new treatment option for patients with hypertrophic cardiomyopathy.

Reference link:https://www.drugs.com